Becker Capital Management Inc. Increases Stake in Hologic, Inc. (NASDAQ:HOLX)

Becker Capital Management Inc. raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,034 shares of the medical equipment provider’s stock after buying an additional 920 shares during the quarter. Becker Capital Management Inc.’s holdings in Hologic were worth $5,914,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in HOLX. Barclays PLC boosted its position in shares of Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after acquiring an additional 231,578 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Hologic during the third quarter worth $93,000. Tidal Investments LLC boosted its stake in Hologic by 60.1% during the third quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider’s stock worth $1,250,000 after buying an additional 5,764 shares during the period. Franklin Resources Inc. boosted its stake in Hologic by 171.7% during the third quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider’s stock worth $22,714,000 after buying an additional 175,855 shares during the period. Finally, Oddo BHF Asset Management Sas purchased a new position in Hologic during the third quarter worth $1,110,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on HOLX. Evercore ISI dropped their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research note on Monday, February 3rd. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Stephens reissued an “overweight” rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic presently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Trading Up 0.5 %

NASDAQ HOLX opened at $58.36 on Wednesday. The company has a fifty day simple moving average of $60.78 and a two-hundred day simple moving average of $69.69. The stock has a market cap of $13.10 billion, a P/E ratio of 18.41, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 12-month low of $55.89 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.